Our founders are building beyond the pre-defined edges of human health. Through the convergence of AI, technology, and biology, and the reimagining of healthcare, we’re the first call for bold entrepreneurs pushing boundaries and leading the way towards better care for all.
From life sciences to care delivery, spanning seed financing through IPO, we’re partnering with a new generation of determined, multidisciplinary entrepreneurs across the entire company‑building journey. Together we are building iconic companies that are radically transforming how we diagnose, treat, and manage disease, while building the healthcare system of tomorrow–a system of Enduring Health (™). Together, we are building the future. The Future is Health.
Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.
Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids. We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in the coming year.
Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed "molecular gates."
Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health. The conversation explores how AI advancements can revolutionize traditional healthcare models by enhancing efficiency, personalizing care journeys, and integrating real-time data insights.
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
10 founders on how tech will make our healthcare system more intuitive, efficient, and cost-effective.
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Catalysts. Conveners. Connective Tissue. Bringing tech-enabled innovations to patients through ecosystem partnerships.
We’re former founders, operators, and entrepreneurs. We’re MDs, PhDs, scientists, and technologists. We bring the know-how and networks of five full operating teams and deep expertise from across our consumer, enterprise, and fintech practices to help founders find their edge.
We win as one team, and we win big.
See Full Team
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
